

THE ROLE OF SURGERY AT THORACIC ESOPHAGEAL CANCER

Montazer Majid m.d

Thorax ward of Imam Reza hospital

Tabriz – winter 2117

HISTORY

- The first ESOPHAGEAL RESECTION WAS > 125Y ago **1877** Czerny at **Heidelberg**
- **Iver lewis – 1946**
- **McKeown – 1962**(3 incisional technique)
- **Transhiatal (orlinger)**
- **Thoracoscopic and Laparoscopic Today**

5 YEAR SURVIVAL

- 2013 ----- > **19%**
- Today ----- > **35%**

WHAT IS PURPOSE ?

Palliation and increase survival and disease free

REDUCTION OF PERIOPERATIVE MORTALITY

- **40%** ----- > 50 YEARS ----- > **3%**


- IMPROVEMENT:

1- PATIENT SELECTION

2- OPERATIVE TECHNIQUE

3- INTENSIVE CARE

4- AGGRESSIVE MANAGEMENT OF PERIOPERATIVE COMPLICATION



- Surgical therapy :
- ***the best chance for cure*** with a complete resection
- ***effective palliation*** with relief of dysphagia
- ***Esophagectomy***
- ***Substitutes***: gastric tube , jejunum , colon
- ***Extent of surgical resection***: up 12 cm & 5cm distal grossly normal
- ***En bloc resection***
- ***Lymph node dissection***

SURGERY OF ESOPHAGEAL CARCINOMA

Operable:

- T4A : Invading pleura – pericardium - diaphragm
- T2A : Simple esophagectomy
- **Surgical option:** one of methods

Inoperable:

- T4B: Aorta – vertebral body – trachea
- Obstruction, trachea esophageal fistula
- **Surgical option:** esophageal bypass+ gastrostomy+ jejenostomy




TABLE 38-1

**Comparison of Transthoracic
and Transhiatal Approaches
to Esophagectomy:
Perioperative Complications**

Complication	Transthoracic	Transhiatal
Blood loss (mL)	1001	728
Operative time (hours)	5.6	4.0
Cardiac complications (%)	6.6	19.5
Pulmonary complications (%)	18.7	12.7
Anastomotic leak (%)	7.2	13.6
Vocal cord paralysis (%)	3.5	9.5
Chyle leak (%)	2.4	1.4
In-hospital mortality (%)	9.2	5.7

Adapted from Hulscher JB, Tijssen JG, Obertop H, et al: Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 72:306–313, 2001.

A TRIAL RANDOMIZED 100 E.C

- Preoperative chemotherapy followed by T.H.E versus T.H.E ALONE:
- SURVIVAL in neoadjuvant group **30%** at 3 y
 - in T.H.E **16%**

A EUROPIAN STUDY RANDOMIZING 382 E.C S.C.C

- Chemo+ tri field en bloc trans thoracic esophagectomy versus esophagectomy alone:
- No difference 5 y survival

WLASH AND COWORKERS RANDOMIZED 113 PATIENT WITH ADENOCARCINOMA

- Surgery alone versus chemoradiation followed surgery
- 5 y survival :
 - **50%** for neo+ surgery
 - **8%** for surgery

پایان